Evidence map›Paper›PMID 33963425›Full record

ArticleEuropean journal of clinical pharmacology2021

Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction.

Leonardo De Luca, Massimo Uguccioni, Enrico Natale, Marco Pugliese, Antonio Terranova, Elisabetta Biffani, Lucia De Lio, Vito Piazza, Rita Lucia Putini, Francesco Musumeci

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Leonardo De LucaDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy. leo.deluca@libero.it.ORCID http://orcid.org/0000-0002-8552-1272
Massimo UguccioniDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Enrico NataleDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Marco PuglieseDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Antonio TerranovaDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Elisabetta BiffaniDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Lucia De LioDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Vito PiazzaDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Rita Lucia PutiniDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
Francesco MusumeciDepartment of Cardiosciences, A. O. San Camillo-Forlanini, Roma, Italy.
IRCCS San Camillo Hospital · ITAzienda Ospedaliera San Camillo-Forlanini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThere is no specific evidence on the antithrombotic management of survivors of out-of-hospital cardiac arrest (OHCA) due to acute myocardial infarction (AMI). We sought to compare the short-term outcome of unfractioned heparin (UFH) vs fondaparinux in OHCA survivors due to AMI admitted in our Institution in the last decade.

methodsWe performed a retrospective cohort study on survivors of OHCA due to AMI managed with UFH or fondaparinux during the hospitalization. The primary outcome was the occurrence of any bleeding, all-cause mortality, cerebrovascular accidents, re-MI, and unplanned revascularization at 1 month. A propensity-score matching was performed to compare the outcome between UFH and fondaparinux.

resultsOut of 2083 AMI patients undergoing successful PCI, OHCA was present in 94 (4.5%): 41 (43.6%) treated with UFH and 53 (56.4%) with fondaparinux. At clinical follow-up, the incidence of the primary outcome was 65.9% in UFH and 35.8% in fondaparinux group (p = 0.007). More than half of the events included in the primary outcome were related to bleeding complications. In the matched cohort of 56 patients, the primary outcome occurred in 46.4% and 25.0% (p = 0.16), while bleeding was present in 32.1% and 7.1% (p = 0.04), in the UFH and fondaparinux group, respectively.

conclusionsThe present analysis suggests that fondaparinux is safer than UFH in the management of OHCA due to AMI by reducing early bleeding complications at one month.

Indexed as

AnticoagulantsFondaparinuxHemorrhageHeparinHumansMyocardial InfarctionOut-of-Hospital Cardiac ArrestPercutaneous Coronary InterventionRetrospective StudiesAnticoagulantsFondaparinuxHeparinAcute myocardial infarctionAnticoagulantsFondaparinuxOut-of-hospital cardiac arrestPercutaneous coronary intervention

Identifiers

PMID33963425
OpenAlexW3159253583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.